Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382586 · ClinicalTrials.gov registry record · Phase 2
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
A Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 10
- Study locations
NCT04382586 is a Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications that has completed, run by BeiGene. The registered enrollment target is 63 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT04382586, a Phase 2 study of COVID-19 and COVID-19 Pulmonary Complications, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Placebo
- DRUG Supportive Care
Study Locations (10)
Massachusetts
- Massachusetts General Hospital - Boston
- The Brigham and Womens Hospital, Inc - Boston
Texas
- Therapeutics Concepts - Houston
- Joe Arrington Cancer Research and Treatment Center - Lubbock
California
- St Jude Medical Center - Fullerton
District of Columbia
- Medstar Heath Research Institute Medstar Washington Hospital Center - Washington D.C.
Georgia
- John D Archbold Memorial Hospital - Thomasville
Illinois
- Loyola University Medical Center - Maywood
New Jersey
- Rutgers University Hospital - Newark
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04382586
The ClinicalTrials.gov registry entry for NCT04382586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT04382586 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Massachusetts, Texas, California.
Frequently Asked Questions
What is clinical trial NCT04382586 about?
NCT04382586 is a clinical study titled "Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants". The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
What is the current status of trial NCT04382586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2020-07-06. Estimated completion is 2021-02-01.
What conditions does trial NCT04382586 study?
This clinical trial studies the following conditions: COVID-19, COVID-19 Pulmonary Complications.
What interventions are being tested in trial NCT04382586?
The interventions under investigation include: Zanubrutinib (DRUG), Placebo (DRUG), Supportive Care (DRUG).
Who is sponsoring clinical trial NCT04382586?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04382586 being conducted?
This trial has 10 study locations across California, District of Columbia, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.